Published in AIDS Weekly and Law, March 18th, 2004
According to recent research published in the Journal of Clinical Microbiology, "A collaborative multicenter study was conducted to evaluate the sensitivity, specificity, and precision of a three-step, fully automated, qualitative microparticle-based enzyme-linked immunoassay (AxSYM HIV Ag/Ab Combo; Abbott Laboratories), designed to simultaneously detect antibodies against human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2), and HIV p24 antigen. A significant reduction in the HIV seroconversion...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.